• - Proportion of patients receiving Macugen monotherapy versus those receiving a combination therapy [ Time Frame: one year ] [ Designated as safety issue: No ]
  
• - Proportion of patients showing stabilization of visual acuity at last follow up [ Time Frame: one year ] [ Designated as safety issue: No ]
  
• - Proportion of patients with improvement in visual acuity at last follow up [ Time Frame: one year ] [ Designated as safety issue: No ]
  
• - Proportion of patients with early lesions showing improvement in visual acuity at last follow up [ Time Frame: one year ] [ Designated as safety issue: No ]
  
• - Average number of injections to achieve improvement in the group showing improvement in visual acuity at last follow up [ Time Frame: one year ] [ Designated as safety issue: No ]
  

• - Average number of injections to achieve stabilization in the group showing stabilization of visual acuity at last follow up [ Time Frame: one year ] [ Designated as safety issue: No ]
  
• - Proportion of patients showing improvement Fundus Fluorescein Angiography (FFA) parameters at last follow up [ Time Frame: one year ] [ Designated as safety issue: No ]
  
• - Average number of injections to achieve improvement of visual acuity in patients with early lesions, in the group showing improvement, at last followup [ Time Frame: one year ] [ Designated as safety issue: No ]
  
• - In the subgroup previously treated by other therapy, proportion of patients showing improvement in visual acuity [ Time Frame: one year ] [ Designated as safety issue: No ]
  
• - Proportion of patients experiencing adverse events, ocular and non-ocular [ Time Frame: one year ] [ Designated as safety issue: Yes ]
  

To be eligible for enrollment in this study, patients must receive the first injection of Macugen intravitreal in at least one eye for treatment of wet AMD. The decision to prescribe Macugen will necessarily precede and will be independent of the decision to enroll patient into the study.

If both eyes of a patient receive injection Macugen, only one eye will be included in the study. If both eyes receive first injection Macugen after initiation of the study, only the first treated eye will be included in the analysis. If one eye has already received Macugen when the study starts and the second eye receives injection after the study initiation, the second eye will be included in the analysis.